MoonLake shareholders approve 5M share increase to equity plan at 2026 AGM

MoonLake Immunotherapeutics

Shareholders approved amendment to 2022 Equity Incentive Plan, adding 5,000,000 Class A shares for awards.
Plan now includes one-year minimum vesting requirement, revised director compensation limits, and term through 2036.
Director Spike Loy re-elected with 92.4% of votes cast; auditor Baker Tilly ratified with 99.9% support.
Advisory vote on executive compensation passed with 98.6% of votes cast in favor.
Total shares authorized under the plan now 9,353,948, subject to adjustment provisions.

item 5.02 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

MoonLake Immunotherapeutics shareholders approved Election of Class I Director Nominee.

Proposal: director election
Outcome: passed

Exact text from the filing

At the Annual Meeting, the Class I director nominee was elected and the other proposals voted on were approved. The final voting results are set forth below: Votes For Votes Withheld Broker Non-Votes Proposal 1. Election of the Class I Director Nominee ● Spike Loy 47,222,233 3,889,131 10,761,142

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

MoonLake Immunotherapeutics shareholders approved Approval of an Amendment and Restatement of the 2022 Equity Incentive Plan.

Proposal: equity plan
Outcome: passed

Exact text from the filing

Proposal 4. Approval of an Amendment and Restatement of the 2022 Equity Incentive Plan 50,599,032 498,186 14,146 10,761,142

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

MoonLake Immunotherapeutics shareholders approved Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor.

Proposal: auditor ratification
Outcome: passed

Exact text from the filing

Proposal 2. Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor 61,831,463 17,522 23,521 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

MoonLake Immunotherapeutics shareholders approved Advisory Vote on Executive Compensation.

Proposal: say on pay
Outcome: passed

Exact text from the filing

Proposal 3. Advisory Vote on Executive Compensation 50,365,168 731,158 15,038 10,761,142

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

MoonLake Immunotherapeutics filing history →

Source: SEC EDGAR

accession 0001213900-26-066821

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.